Which of the following statements regarding tofacitinib is correct?
A. It is a new injectable biologic agent indicated for the treatment of rheumatoid arthritis.
B. It has a boxed warning for the risk of fetal abnormalities.
C. It should be used with a biologic DMARD.
D. It is an inhibitor of Janus Kinase enzymes.
E. The brand name is Aubagio